Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men

Michael Dale Lairmore, J. M. Jason, T. M. Hartley, R. F. Khabbaz, B. De, B. L. Evatt

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Concern for transmission of human T-cell lymphotropic virus, type 1 ((HTLV-1) infection to recipients of infected cellular blood products has prompted development of tests to eliminate blood units with HTLV-I antibodies. Most hemophilic men from the United States became infected with human immunodeficiency virus (HIV) before HIV donor screening and before blood products were processed to inactivate the virus. To assess whether these men might also be infected with HTLV-I, we examined the HTLV-I antibody status of 127 factor VIII (hemophilia A) recipients and 71 factor IX (hemophilia B) recipients. One HIV-seronegative and four HIV-seropositive persons were HTLV-I reactive by enzyme-linked immunosorbent assay (ELISA). Four of five ELISA-reactive serum samples were negative by HTLV-I immunoblot assay (IB); 1 reactive and 1 borderline reactive serum were indeterminate on IB (p19 reactivity), but negative by radioimmunoprecipitation assay (RIPA). Peripheral blood mononuclear cells from one patient with indeterminate HTLV-I IB were negative for HTLV-I genomic sequences by polymerase chain reaction. The other indeterminate patient's serum antibody pattern was stable over a 2-year period, suggesting this was not an instance of early HTLV-I seroconversion. These results reaffirm the safety of factor components in the United States with regard to HTLV-I but emphasize the importance and need for further testing of reactive HTLV-I ELISA results with a second more specific technique.

Original languageEnglish (US)
Pages (from-to)2596-2599
Number of pages4
JournalBlood
Volume74
Issue number7
StatePublished - 1989
Externally publishedYes

Fingerprint

Human T-lymphotropic virus 1
T-cells
Coinfection
Viruses
Assays
HIV
T-Lymphocytes
Immunosorbents
Blood
HTLV-I Antibodies
Enzyme-Linked Immunosorbent Assay
Enzymes
Factor IX
Radioimmunoprecipitation Assay
Serum
Polymerase chain reaction
Factor VIII
Hemophilia B
Donor Selection
Hemophilia A

ASJC Scopus subject areas

  • Hematology

Cite this

Lairmore, M. D., Jason, J. M., Hartley, T. M., Khabbaz, R. F., De, B., & Evatt, B. L. (1989). Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men. Blood, 74(7), 2596-2599.

Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men. / Lairmore, Michael Dale; Jason, J. M.; Hartley, T. M.; Khabbaz, R. F.; De, B.; Evatt, B. L.

In: Blood, Vol. 74, No. 7, 1989, p. 2596-2599.

Research output: Contribution to journalArticle

Lairmore, MD, Jason, JM, Hartley, TM, Khabbaz, RF, De, B & Evatt, BL 1989, 'Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men', Blood, vol. 74, no. 7, pp. 2596-2599.
Lairmore, Michael Dale ; Jason, J. M. ; Hartley, T. M. ; Khabbaz, R. F. ; De, B. ; Evatt, B. L. / Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men. In: Blood. 1989 ; Vol. 74, No. 7. pp. 2596-2599.
@article{cf7ab1a709bb4558931cf9408967f1e4,
title = "Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men",
abstract = "Concern for transmission of human T-cell lymphotropic virus, type 1 ((HTLV-1) infection to recipients of infected cellular blood products has prompted development of tests to eliminate blood units with HTLV-I antibodies. Most hemophilic men from the United States became infected with human immunodeficiency virus (HIV) before HIV donor screening and before blood products were processed to inactivate the virus. To assess whether these men might also be infected with HTLV-I, we examined the HTLV-I antibody status of 127 factor VIII (hemophilia A) recipients and 71 factor IX (hemophilia B) recipients. One HIV-seronegative and four HIV-seropositive persons were HTLV-I reactive by enzyme-linked immunosorbent assay (ELISA). Four of five ELISA-reactive serum samples were negative by HTLV-I immunoblot assay (IB); 1 reactive and 1 borderline reactive serum were indeterminate on IB (p19 reactivity), but negative by radioimmunoprecipitation assay (RIPA). Peripheral blood mononuclear cells from one patient with indeterminate HTLV-I IB were negative for HTLV-I genomic sequences by polymerase chain reaction. The other indeterminate patient's serum antibody pattern was stable over a 2-year period, suggesting this was not an instance of early HTLV-I seroconversion. These results reaffirm the safety of factor components in the United States with regard to HTLV-I but emphasize the importance and need for further testing of reactive HTLV-I ELISA results with a second more specific technique.",
author = "Lairmore, {Michael Dale} and Jason, {J. M.} and Hartley, {T. M.} and Khabbaz, {R. F.} and B. De and Evatt, {B. L.}",
year = "1989",
language = "English (US)",
volume = "74",
pages = "2596--2599",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Absence of human T-cell lymphotropic virus type I coinfection in human immunodeficiency virus-infected hemophilic men

AU - Lairmore, Michael Dale

AU - Jason, J. M.

AU - Hartley, T. M.

AU - Khabbaz, R. F.

AU - De, B.

AU - Evatt, B. L.

PY - 1989

Y1 - 1989

N2 - Concern for transmission of human T-cell lymphotropic virus, type 1 ((HTLV-1) infection to recipients of infected cellular blood products has prompted development of tests to eliminate blood units with HTLV-I antibodies. Most hemophilic men from the United States became infected with human immunodeficiency virus (HIV) before HIV donor screening and before blood products were processed to inactivate the virus. To assess whether these men might also be infected with HTLV-I, we examined the HTLV-I antibody status of 127 factor VIII (hemophilia A) recipients and 71 factor IX (hemophilia B) recipients. One HIV-seronegative and four HIV-seropositive persons were HTLV-I reactive by enzyme-linked immunosorbent assay (ELISA). Four of five ELISA-reactive serum samples were negative by HTLV-I immunoblot assay (IB); 1 reactive and 1 borderline reactive serum were indeterminate on IB (p19 reactivity), but negative by radioimmunoprecipitation assay (RIPA). Peripheral blood mononuclear cells from one patient with indeterminate HTLV-I IB were negative for HTLV-I genomic sequences by polymerase chain reaction. The other indeterminate patient's serum antibody pattern was stable over a 2-year period, suggesting this was not an instance of early HTLV-I seroconversion. These results reaffirm the safety of factor components in the United States with regard to HTLV-I but emphasize the importance and need for further testing of reactive HTLV-I ELISA results with a second more specific technique.

AB - Concern for transmission of human T-cell lymphotropic virus, type 1 ((HTLV-1) infection to recipients of infected cellular blood products has prompted development of tests to eliminate blood units with HTLV-I antibodies. Most hemophilic men from the United States became infected with human immunodeficiency virus (HIV) before HIV donor screening and before blood products were processed to inactivate the virus. To assess whether these men might also be infected with HTLV-I, we examined the HTLV-I antibody status of 127 factor VIII (hemophilia A) recipients and 71 factor IX (hemophilia B) recipients. One HIV-seronegative and four HIV-seropositive persons were HTLV-I reactive by enzyme-linked immunosorbent assay (ELISA). Four of five ELISA-reactive serum samples were negative by HTLV-I immunoblot assay (IB); 1 reactive and 1 borderline reactive serum were indeterminate on IB (p19 reactivity), but negative by radioimmunoprecipitation assay (RIPA). Peripheral blood mononuclear cells from one patient with indeterminate HTLV-I IB were negative for HTLV-I genomic sequences by polymerase chain reaction. The other indeterminate patient's serum antibody pattern was stable over a 2-year period, suggesting this was not an instance of early HTLV-I seroconversion. These results reaffirm the safety of factor components in the United States with regard to HTLV-I but emphasize the importance and need for further testing of reactive HTLV-I ELISA results with a second more specific technique.

UR - http://www.scopus.com/inward/record.url?scp=0024463874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024463874&partnerID=8YFLogxK

M3 - Article

C2 - 2508796

AN - SCOPUS:0024463874

VL - 74

SP - 2596

EP - 2599

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -